Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma

NCT01508364 · clinicaltrials.gov ↗

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Renal Cell

Interventions

DRUG: Sorafenib (Nexavar, BAY 43-9006)

Sponsor

Bayer